Clinical Trial Update: A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC [Phase 2]

View source ↗

Summary

A Phase II clinical trial is evaluating RC108 in combination with furmonertinib as first-line therapy for EGFR-mutated, MET-positive unresectable locally advanc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Furmonertinib (furmonertinib)
• RC108

Snippet

Sponsor: RemeGen Co., Ltd. | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: RECRUITING